Sagespring Wealth Partners LLC Purchases New Stake in Insmed, Inc. $INSM

Sagespring Wealth Partners LLC purchased a new stake in Insmed, Inc. (NASDAQ:INSM) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,528 shares of the biopharmaceutical company’s stock, valued at approximately $254,000.

Several other hedge funds have also bought and sold shares of INSM. GAMMA Investing LLC grew its position in Insmed by 62.0% in the 1st quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 386 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in Insmed by 16.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 3,772 shares of the biopharmaceutical company’s stock worth $288,000 after acquiring an additional 541 shares during the last quarter. Sowell Financial Services LLC purchased a new position in Insmed during the 1st quarter worth $255,000. Avior Wealth Management LLC boosted its holdings in Insmed by 82.2% during the 1st quarter. Avior Wealth Management LLC now owns 4,151 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 1,873 shares during the last quarter. Finally, Whalen Wealth Management Inc. purchased a new position in Insmed during the 1st quarter worth $217,000.

Insider Activity at Insmed

In other news, CEO William Lewis sold 6,865 shares of Insmed stock in a transaction on Monday, August 18th. The stock was sold at an average price of $128.40, for a total transaction of $881,466.00. Following the sale, the chief executive officer directly owned 233,924 shares in the company, valued at $30,035,841.60. The trade was a 2.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Melvin Md Sharoky sold 10,000 shares of the business’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the sale, the director owned 262,675 shares in the company, valued at $38,190,318.25. This represents a 3.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 211,057 shares of company stock worth $27,438,126. 3.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on INSM shares. Cowen reaffirmed a “buy” rating on shares of Insmed in a report on Thursday, October 2nd. Evercore ISI reaffirmed an “outperform” rating and set a $180.00 price objective on shares of Insmed in a report on Wednesday, October 1st. Stifel Nicolaus lifted their price objective on shares of Insmed from $121.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, August 14th. The Goldman Sachs Group lifted their price objective on shares of Insmed from $121.00 to $196.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Finally, William Blair started coverage on shares of Insmed in a report on Wednesday, August 20th. They set an “outperform” rating on the stock. Nineteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $152.88.

Insmed Trading Up 1.6%

NASDAQ INSM opened at $165.76 on Friday. The stock has a market capitalization of $35.04 billion, a price-to-earnings ratio of -29.03 and a beta of 1.03. Insmed, Inc. has a one year low of $60.40 and a one year high of $166.44. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The business’s fifty day moving average is $143.38 and its 200-day moving average is $105.05.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company’s revenue for the quarter was up 18.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. Equities research analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.